culver-city
(10)
MMGY Wagstaff knows who gets a seat at the table
A restaurant publicist grew into a hospitality specialist by understanding the people behind the plate. Inside Wagstaff’s business of turning food, drink and travel into stories that get picked up.
Eyes of the World Media Group makes the complicated watchable
A Culver City studio put brain science, engineering ethics and world population data into forms people could actually use. Its most revealing product comes in three parts.
JK & Co. knows what to keep
A storage building becomes an art gallery. A working winery becomes a place to linger. Inside the Los Angeles studio finding new uses for buildings that already have a past.
The Chambers Group knows where the audience is hiding
From supermarket packaging to celebrity feeds and hotel-room televisions, this family agency follows attention wherever it goes. Its most revealing sales pitch comes with a $498,000 email bill.
WC+A Knows How to Make an Entrance
From a kitchen-table start to Fantastic Four key art, WC+A built a business around the images that sell entertainment. Its next act has a new name: MACH27.
Katie Babineau
Katie Babineau is the Chief Marketing Officer of Beyond Yoga, the Culver City premium activewear brand acquired by Levi Strauss & Co. in 2021. She spent roughly fifteen years in consumer technology - Sony Electronics, GoPro, Apple via TBWA\Media Arts Lab, and Snap Inc., where she was Global Head of Marketing - before joining Beyond Yoga as VP of Marketing in 2024 and stepping up to CMO. In 2025 she led the brand's first full reset, a platform called Seek Beyond built around the idea of progress over perfection, with actor and writer Issa Rae as the brand's first celebrity partner writing and performing a spoken-word anthem. She brings a test-and-learn technology mindset to apparel, argues loudly that brand and growth marketing should never be separated, and prefers hyperlocal, in-person community events to another round of picture-perfect ad creative.
Beyond Yoga
Beyond Yoga is a Culver City, California activewear and athleisure brand founded in 2005 by Jodi Guber Brufsky and Michelle Wahler. Built around a body-positive, size-inclusive philosophy (XXS to 3X) and its signature buttery-soft Spacedye fabric, the female-founded label makes leggings, sports bras, loungewear, and lifestyle apparel designed to move from studio to street. Acquired by Levi Strauss & Co. in 2021 for roughly $400 million, Beyond Yoga has grown past $100 million in annual revenue and is expanding its physical retail footprint under CEO Nancy Green.
Daniel's Jewelers
Daniel's Jewelers is a family-owned American fine jewelry retailer founded in 1948 and headquartered in Culver City, California. Operating more than 100 stores across California, Arizona, Texas, Nevada, New Mexico and Florida plus an e-commerce site, the company sells diamonds, watches, engagement rings and gifts at accessible price points. Its defining feature is dignified in-store financing that extends credit to underserved shoppers regardless of income or credit history, a model that has made it a fixture in Hispanic and multigenerational communities under the banner 'Own the Dream.'
Sam Pressman
Sam Pressman is the CEO of Pressman Film, the storied independent studio his father Edward R. Pressman founded in 1969 and that backed American Psycho, Wall Street, Badlands and The Crow. A Stanford Film & Media Studies graduate who grew up on his father's sets, Sam took the helm after Ed's death in 2023 and is betting that independent cinema's next chapter runs on radical filmmakers, crowd-sourced financing, virtual reality and AI - while keeping his father's motto, 'every film is a miracle,' close.
TORL BioTherapeutics LLC
TORL BioTherapeutics is a clinical-stage biopharmaceutical company in Culver City, California developing antibody-based cancer therapies, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Built on discoveries from the UCLA laboratory of Dennis Slamon - the scientist behind Herceptin and Ibrance - TORL is advancing a pipeline against novel cancer targets such as Claudin 6, Claudin 18.2, CDH17, and DLK1. Its lead program, TORL-1-23 (ixotatug vedotin), a CLDN6-targeted ADC, is in pivotal trials for platinum-resistant ovarian cancer. The company has raised over $450 million across multiple rounds, including a $96 million Series C in October 2025.